These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

728 related articles for article (PubMed ID: 21866545)

  • 41. Subtype distribution and long-term titer fluctuation patterns of serum anti-Epstein-Barr virus antibodies in a non-nasopharyngeal carcinoma population from an endemic area in South China: a cohort study.
    Du JL; Chen SH; Huang QH; Xie SH; Ye YF; Gao R; Guo J; Yang MJ; Liu Q; Hong MH; Cao SM
    Chin J Cancer; 2016 Aug; 35(1):78. PubMed ID: 27527073
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic implication of pretreatment titer of serum immunoglobulin A against Epstein-Barr virus capsid antigen in nasopharyngeal carcinoma patients in Sihui, Guangdong.
    Ling W; Cao SM; Huang QH; Li YH; Deng MQ
    Ai Zheng; 2009 Jan; 28(1):57-9. PubMed ID: 19448418
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nasopharyngeal Epstein-Barr Virus Load: An Efficient Supplementary Method for Population-Based Nasopharyngeal Carcinoma Screening.
    Chen Y; Zhao W; Lin L; Xiao X; Zhou X; Ming H; Huang T; Liao J; Li Y; Zeng X; Huang G; Ye W; Zhang Z
    PLoS One; 2015; 10(7):e0132669. PubMed ID: 26151639
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Prognostic significance of serum anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma].
    Cai YL; Li J; Lu AY; Zhong WM; Zheng YM; Gao JQ; Zeng H; Chen WS; Liang W; Tang MZ
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2013 Apr; 27(2):119-22. PubMed ID: 24044217
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination of Epstein-Barr virus scaffold (BdRF1/VCA-p40) and small capsid protein (BFRF3/VCA-p18) into a single molecule for improved serodiagnosis of acute and malignant EBV-driven disease.
    Fachiroh J; Stevens SJ; Haryana SM; Middeldorp JM
    J Virol Methods; 2010 Oct; 169(1):79-86. PubMed ID: 20621126
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody.
    Leung SF; Tam JS; Chan AT; Zee B; Chan LY; Huang DP; Van Hasselt A; Johnson PJ; Lo YM
    Clin Chem; 2004 Feb; 50(2):339-45. PubMed ID: 14684618
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fluctuations of epstein-barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up.
    Cao SM; Liu Z; Jia WH; Huang QH; Liu Q; Guo X; Huang TB; Ye W; Hong MH
    PLoS One; 2011 Apr; 6(4):e19100. PubMed ID: 21544243
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Study on sero-diagnosis of nasopharyngeal carcinoma using a dual antibody test against recombinant Epstein-Barr virus antigens.
    Gu YL; Zhang CQ; Ng SP; Zong YS; Liang YJ; Chen YL
    Ai Zheng; 2003 Sep; 22(9):903-6. PubMed ID: 12969518
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence of IgA specific antibodies to Epstein-Barr virus capsid and early antigens in nasopharyngeal carcinoma.
    Puthavathana P; Kositanont U; Chongkolwatana C; Metheetrairut C; Chantarakul N; Nuntarakchaikul S; Wasi C
    Asian Pac J Allergy Immunol; 1993 Jun; 11(1):39-43. PubMed ID: 8216557
    [TBL] [Abstract][Full Text] [Related]  

  • 50. IgA directed against early antigen of Epstein-Barr virus is no specific marker for the diagnosis of nasopharyngeal carcinoma.
    Sigel G; Schillinger M; Henninger K; Bauer G
    J Med Virol; 1994 Jul; 43(3):222-7. PubMed ID: 7931181
    [TBL] [Abstract][Full Text] [Related]  

  • 51. IgA antibodies against the Epstein-Barr nuclear antigen1 as a valuable biomarker for the diagnosis of nasopharyngeal carcinoma in Tunisian patients.
    Ayadi W; Karray-Hakim H; Feki L; Khabir A; Boudawara T; Ghorbel A; Daoud J; Frikha M; Hammami A
    J Med Virol; 2009 Aug; 81(8):1412-21. PubMed ID: 19551836
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Significance of specific Epstein-Barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharyngeal carcinoma patients.
    Hadar T; Rahima M; Kahan E; Sidi J; Rakowsky E; Sarov B; Sarov I
    J Med Virol; 1986 Dec; 20(4):329-39. PubMed ID: 3025351
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dried-blood sampling for epstein-barr virus immunoglobulin G (IgG) and IgA serology in nasopharyngeal carcinoma screening.
    Fachiroh J; Prasetyanti PR; Paramita DK; Prasetyawati AT; Anggrahini DW; Haryana SM; Middeldorp JM
    J Clin Microbiol; 2008 Apr; 46(4):1374-80. PubMed ID: 18256216
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Relationship Between Environmental Factors and the Profile of Epstein-Barr Virus Antibodies in the Lytic and Latent Infection Periods in Healthy Populations from Endemic and Non-Endemic Nasopharyngeal Carcinoma Areas in China.
    He YQ; Xue WQ; Xu FH; Xu YF; Zhang JB; Yu HL; Feng QS; Chen LZ; Cao SM; Liu Q; Mu J; Zeng YX; Jia WH
    EBioMedicine; 2018 Apr; 30():184-191. PubMed ID: 29606628
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Detection of serum Epstein-Barr virus antibody level by ELISA in normal populations and nasopharyngeal carcinoma patients in Zhongshan City of China].
    Cheng MT; Cheng WM; Ji MF; Liang JS
    Di Yi Jun Yi Da Xue Xue Bao; 2002 Sep; 22(9):817-8, 822. PubMed ID: 12297441
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of Epstein-Barr virus antibodies EA-IgG, Rta-IgG, and VCA-IgA in nasopharyngeal carcinoma and their use in a combined diagnostic assay.
    Li Y; Wang K; Yin SK; Zheng HL; Min DL
    Genet Mol Res; 2016 Mar; 15(1):. PubMed ID: 27050964
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
    Zheng XH; Lu LX; Li XZ; Jia WH
    Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of Chemiluminescence Immunoassays on VCA-IgA and EBNA1-IgA Antibodies of Epstein-Barr Virus in Diagnosing Nasopharyngeal Carcinoma.
    Yu X; Li F; Cheng W; Wu B; Fang H; Xia F; Gong Y; Yu W; Liao P; Cao Y; Yang F; Zhu H; Li J; Huang Y; Gan L; Zhang L; Lou Y; Ji M
    J Cancer; 2020; 11(24):7176-7183. PubMed ID: 33193880
    [No Abstract]   [Full Text] [Related]  

  • 59. Screening for nasopharyngeal carcinoma with an ELISA using the Epstein-Barr virus nuclear antigen, EBNA 1: a complementary test to the IgA/VCA immunofluorescence assay.
    Cheng HM; Foong YT; Mathew A; Sam CK; Dillner J; Prasad U
    J Virol Methods; 1993 Apr; 42(1):45-51. PubMed ID: 7686558
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epstein-Barr virus serology in the diagnosis of nasopharyngeal carcinoma.
    Wong MM; Lye MS; Cheng HM; Sam CK
    Asian Pac J Allergy Immunol; 2005 Mar; 23(1):65-7. PubMed ID: 15997877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.